# High Compliance With The AASLD Cirrhosis Quality Measures Is Associated With Improved Outcomes In Cirrhosis With Acute Variceal Bleeding: Singapore Nationwide Audit

\*Yu Jun WONG<sup>1,2</sup>, \*Alyssa SIM<sup>3</sup>, Margaret TENG<sup>4</sup>, Marianne Anastasia DE ROZA<sup>5</sup>, Garrett KANG<sup>1</sup>, Jonathan KUANG<sup>3</sup>, Htay Myat THET<sup>6</sup>, En Xian Sarah LOW<sup>6</sup>, Kai LIM<sup>7</sup>, Pooi Ling LOI<sup>7</sup>, Guan Sen KEW<sup>4</sup>, Boon Yew Andrew KWEK<sup>1,2</sup>, Wei Lyn YANG<sup>3</sup>, #Guan Wee WONG<sup>6</sup>, #Jason CHANG<sup>7</sup>

\*Co-first authors; #Co-last authors

<sup>1</sup>Department of Gastroenterology & Hepatology, Changi General Hospital, Singapore, <sup>2</sup>Duke-NUS Medical School, Singapore; <sup>3</sup>Department of Gastroenterology & Hepatology, Tan Tock Seng Hospital, Singapore, <sup>4</sup>Division of Gastroenterology & Hepatology, National University Hospital; <sup>5</sup>Department of Gastroenterology & Hepatology, Sengkang General Hospital, Singapore General Hospital; <sup>6</sup>Division of Gastroenterology, Department of Medicine, Ng Teng Fong Hospital, Singapore; <sup>7</sup>Department of Gastroenterology & Hepatology, Singapore General Hospital

#### BACKGROUND & AIMS

- Acute variceal bleeding (AVB) is a common life-threatening complication of liver cirrhosis with high 6-week mortality of 10-20%, and rebleeding rate of up to 60% in high-risk patients
- AASLD cirrhosis quality measures<sup>1</sup> were introduced in 2019 to assess quality of care provided to cirrhosis patients, but realworld adherence remains unclear
- The Singapore Nationwide Variceal Bleeding Audit was proposed to address the following gaps
  - Real-world adherence to clinical practice guidelines when managing AVB in Singapore
  - Lack of updated and representative data on clinical outcomes of AVB in Singapore
- Hence, the aims of the study were:
  - To determine real-world compliance rate to AASLD cirrhosis quality measures on AVB
  - To determine clinical outcomes of AVB early rebleeding within 5 days, and 6-week mortality

# **METHODS**



- All public hospitals in Singapore were invited to participate in the audit
- All AVB patients hospitalised from 1 Jan 2015 31 Dec 2021 were included
- Standardised methods were used across all sites for patient identification, data extraction, and reporting
- All patient records were individually reviewed by investigators and data was extracted using a standardised template
- AVB patients re-admitted to another hospital following their index AVB episode were excluded to avoid duplication
- De-identified data was then sent to coordinating site (CGH) for analysis

#### Outcome measures

- Early rebleeding within 5 days
- Mortality at 6 weeks

#### Process measures

- Prophylactic antibiotics within 12 hours of admission
- Vasoactive agents within 12 hours of admission
- Early endoscopy within 12 hours of admission
- Achievement of haemostasis during index endoscopy
- Endoscopy treatment and non-selective beta-blocker (NSBB) before discharge

#### CONCLUSION

- Overall adherence to AASLD cirrhosis quality measures was high (>80%) and adherence was associated with improved AVB outcomes
- Child-Pugh class C patients with AVB had poor outcomes despite high adherence to quality measures
- There was low uptake of pre-emptive TIPSS among AVB patients in Singapore

Acknowledgements: all participating sites, Gastroenterological Society of Singapore (GESS)

<u>References</u> <sup>1</sup>Kanwal F, Tapper EB, Ho C, et al. Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the AASLD. Hepatology 2019

## RESULTS

Early rebleeding within 5 days: 6.2%

6-week mortality: 13.7% 1-year mortality: 26.2%

	Overell	
	Overall n = 690	
Demographics	11 030	
Age	62	
Male Gender (%)	74	
Ethnicity (%)		
- Chinese	63	
- Malay	21	
- Indian	11	
Disease Characteristics		
Severity of cirrhosis (%)		
- Child-Pugh A	35.2	
- Child-Pugh B	58.5	
- Child-Pugh C	6.3	
- MELD >15	34.6	
Complications		
Prior variceal bleeding (%)	18	
Ascites (%)	29	
Prior HE (%)	35	
HCC (%)	27	
Portal vein thrombosis (%)	17	





Table 1. Baseline demographics and disease characteristics.

### **Compliance with AASLD cirrhosis quality measures**






Figure 1. Association between adherence to AASLD quality measures and AVB outcomes




Figure 2. Association between Child-Pugh class and AVB outcomes in adherent patients

• 16.1% of AVB patients were eligible for pre-emptive TIPSS (pTIPS), but only 3.7% of patients underwent pTIPS